Purespring Therapeutics develops AAV gene therapies specifically targeting podocytes to treat glomerular kidney diseases, including IgA nephropathy. The company addresses the lack of effective treatments for patients at risk of progressing to end-stage renal disease, offering a potential alternative to dialysis and kidney transplantation.
Funding
$164.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GHFounders
Product
Problem
Glomerular kidney diseases, including IgA nephropathy, affect millions globally and often progress to end-stage renal disease, requiring dialysis or kidney transplantation. Current treatments are lacking, leaving patients with limited options to prevent disease progression and the associated decline in quality of life.
Solution
Purespring Therapeutics is developing adeno-associated virus (AAV) gene therapies that target podocytes, specialized cells within the kidney's glomeruli, to treat glomerular kidney diseases. Their proprietary platform delivers gene therapies directly to podocytes, offering a novel approach to address both inherited and common kidney diseases. The lead program, PS-002, modulates complement signaling within the glomeruli, with initial focus on IgA nephropathy and potential expansion to other complement-driven glomerular diseases. By targeting the underlying genetic and molecular mechanisms of these diseases, Purespring aims to prevent disease progression, reduce the need for dialysis or transplantation, and improve patient outcomes.
Target Audience
The primary target audience includes patients with glomerular kidney diseases, particularly IgA nephropathy, and healthcare providers specializing in nephrology and gene therapy.
Features
- AAV gene therapy platform for targeted delivery to podocytes
- PS-002 lead program focused on complement modulation in IgA nephropathy
- Potential application to a range of genetic and non-genetic glomerular diseases
- Disease-modifying approach to prevent progression to end-stage renal disease